{"schema_version":"secwatch.filing_event.v1","accession":"0001501697-25-000041","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.571191+00:00","generated_at":"2026-05-17T00:15:32.631934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"X4 Pharma Q3 net loss $29.8M ($0.69/sh); cash runway to end 2028 after $240.3M financing","bullets":["Q3 net product sales XOLREMDI $1.6M vs $0.6M YoY; net loss $0.69/sh vs $5.48/sh in Q3 2024.","Raised $240.3M gross via public offering and upsized private placement; cash runway extended to end of 2028.","50% workforce reduction yields ~$13M annualized cost savings; focus on Phase 3 4WARD chronic neutropenia trial.","Enrollment target for 4WARD increased to 176 patients; expected completion Q3 2026; sNDA potential in chronic neutropenia.","Deprioritized XOLREMDI commercialization for WHIM syndrome; John Volpone promoted to COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001501697-25-000041","json":"https://secwatch.observer/filing/0001501697-25-000041.json","markdown":"https://secwatch.observer/filing/0001501697-25-000041.md","text":"https://secwatch.observer/filing/0001501697-25-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/0001501697-25-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/xfor-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:15:32.631934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}